Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566795 · ClinicalTrials.gov registry record · Phase 3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
A Phase 3 study of Low Grade Glioma and Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, sponsored by Day One Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT05566795 is a Phase 3 study of Low Grade Glioma and Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma that is actively recruiting participants, run by Day One Biopharmaceuticals. The registered enrollment target is 400 participants, above the 96-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (317% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05566795, a Phase 3 study of Low Grade Glioma and Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, is actively recruiting participants, sponsored by Day One Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Conditions Studied
Interventions
- DRUG Tovorafenib
- DRUG Chemotherapeutic Agent
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County Main Campus - Orange - Orange
- Packard Children's Hospital Stanford - Palo Alto
- UCSF Benioff Children's Hospital - San Francisco
Florida
- University of Florida Health - Gainesville
- Nicklaus Children's Hospital - Miami
- Arnold Palmer Hospital for Children - Orlando
- Johns Hopkins All Children's Hospital - St. Petersburg
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- University of Chicago - Chicago
Alabama
- Children's of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Connecticut
- Connecticut Children's Medical Center - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2031-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05566795
The ClinicalTrials.gov registry entry for NCT05566795 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (317% higher). The listed sponsor is Day One Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Tovorafenib is the first listed.
NCT05566795 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05566795 about?
NCT05566795 is a clinical study titled "DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)". This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibro...
What is the current status of trial NCT05566795?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-02-27. Estimated completion is 2031-06.
What conditions does trial NCT05566795 study?
This clinical trial studies the following conditions: Low Grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma.
What interventions are being tested in trial NCT05566795?
The interventions under investigation include: Tovorafenib (DRUG), Chemotherapeutic Agent (DRUG).
Who is sponsoring clinical trial NCT05566795?
This trial is sponsored by Day One Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05566795 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
-
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
Explore more on PlainTrial
Low Grade Glioma
All registered trials for this condition
Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.